FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021517488> ?p ?o ?g. }

• W2021517488 endingPage "1492" @default.
• W2021517488 startingPage "1487" @default.
• W2021517488 abstract "To explore the effect of granulocyte macrophage colony stimulating factor (GM-CSF) on viral load and CD4 cell count during interruption of highly active antiretroviral therapy (HAART).Patients on effective HAART (CD4 cell count > 400 x 10(6)/l; viral load < 50 HIV RNA copies/ml) were randomized to one of two groups: 12 weeks' treatment interruption plus, during the first 4 weeks, 300 microg GM-CSF (Leucomax-Novartis) by subcutaneous injection three times weekly (GM-CSF group); 12 weeks' scheduled treatment interruption (STI-only group). Viral load, CD4 cell count, clinical events and side effects of treatment were monitored.Thirty-three patients, 15 in the GM-CSF group and 18 in the STI-only group, were evaluated according to the intention-to-treat principle. The two groups were well matched with regard to pre-HAART viral loads and CD4 cell counts. During STI, viraemia was approximately two to three times lower in the group receiving GM-CSF (max 4.97 versus 5.45 in STI-only group; P = 0.03). Fifteen out of 17 patients in the STI-only group showed a decrease in their CD4 cell count between weeks 0 and 4 (median decrease 231 x 10(6) cells/l; P < 0.001); there was no such tendency in the GM-CSF group (P = non-significant when comparing CD4 cell counts at weeks 0 and 4). The median CD4 cell AUC (area under the curve) from week 0 to week 12 was higher in the GM-CSF group (9166 cells.week) than in patients without GM-CSF (7257), P = 0.02. GM-CSF produced local reactions in 88% of patients, and generalized symptoms such as fever, back pain or headache in 82% of patients. Seventy-six percent of patients completed the planned course of 12 injections.The administration of GM-CSF blunted the viral rebound following interruption of HAART, and largely prevented a decrease of CD4 cell counts during a 12-weeks-treatment interruption. A better understanding of the underlying mechanism(s) may help to identify synergistic treatment targets and improved administration protocols to enhance control of chronic HIV infection." @default.
• W2021517488 created "2016-06-24" @default.
• W2021517488 creator A5003503698 @default.
• W2021517488 creator A5008537578 @default.
• W2021517488 creator A5033462113 @default.
• W2021517488 creator A5034838519 @default.
• W2021517488 creator A5054829374 @default.
• W2021517488 creator A5057999899 @default.
• W2021517488 creator A5060213700 @default.
• W2021517488 creator A5066398751 @default.
• W2021517488 creator A5073850808 @default.
• W2021517488 creator A5074362033 @default.
• W2021517488 creator A5080523158 @default.
• W2021517488 creator A5088187599 @default.
• W2021517488 creator A5090938532 @default.
• W2021517488 date "2003-07-01" @default.
• W2021517488 modified "2023-09-23" @default.
• W2021517488 title "A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART" @default.
• W2021517488 cites W164824509 @default.
• W2021517488 cites W1977913554 @default.
• W2021517488 cites W1979341960 @default.
• W2021517488 cites W1984501809 @default.
• W2021517488 cites W1991148746 @default.
• W2021517488 cites W1997346247 @default.
• W2021517488 cites W2006255713 @default.
• W2021517488 cites W2011406016 @default.
• W2021517488 cites W2013068560 @default.
• W2021517488 cites W2045837677 @default.
• W2021517488 cites W2046027100 @default.
• W2021517488 cites W2050584993 @default.
• W2021517488 cites W2057178907 @default.
• W2021517488 cites W2060435945 @default.
• W2021517488 cites W2063610820 @default.
• W2021517488 cites W2081751774 @default.
• W2021517488 cites W2086679219 @default.
• W2021517488 cites W2088287053 @default.
• W2021517488 cites W2106051882 @default.
• W2021517488 cites W2111176834 @default.
• W2021517488 cites W2133866490 @default.
• W2021517488 cites W2137611357 @default.
• W2021517488 cites W2138905511 @default.
• W2021517488 cites W2149244682 @default.
• W2021517488 cites W2159689940 @default.
• W2021517488 cites W2412357936 @default.
• W2021517488 cites W2419180378 @default.
• W2021517488 cites W2774292278 @default.
• W2021517488 cites W33719718 @default.
• W2021517488 cites W4245586021 @default.
• W2021517488 cites W4322388705 @default.
• W2021517488 doi "https://doi.org/10.1097/00002030-200307040-00009" @default.
• W2021517488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12824786" @default.
• W2021517488 hasPublicationYear "2003" @default.
• W2021517488 type Work @default.
• W2021517488 sameAs 2021517488 @default.
• W2021517488 citedByCount "25" @default.
• W2021517488 countsByYear W20215174882012 @default.
• W2021517488 countsByYear W20215174882013 @default.
• W2021517488 countsByYear W20215174882014 @default.
• W2021517488 countsByYear W20215174882015 @default.
• W2021517488 countsByYear W20215174882019 @default.
• W2021517488 countsByYear W20215174882021 @default.
• W2021517488 crossrefType "journal-article" @default.
• W2021517488 hasAuthorship W2021517488A5003503698 @default.
• W2021517488 hasAuthorship W2021517488A5008537578 @default.
• W2021517488 hasAuthorship W2021517488A5033462113 @default.
• W2021517488 hasAuthorship W2021517488A5034838519 @default.
• W2021517488 hasAuthorship W2021517488A5054829374 @default.
• W2021517488 hasAuthorship W2021517488A5057999899 @default.
• W2021517488 hasAuthorship W2021517488A5060213700 @default.
• W2021517488 hasAuthorship W2021517488A5066398751 @default.
• W2021517488 hasAuthorship W2021517488A5073850808 @default.
• W2021517488 hasAuthorship W2021517488A5074362033 @default.
• W2021517488 hasAuthorship W2021517488A5080523158 @default.
• W2021517488 hasAuthorship W2021517488A5088187599 @default.
• W2021517488 hasAuthorship W2021517488A5090938532 @default.
• W2021517488 hasBestOaLocation W20215174881 @default.
• W2021517488 hasConcept C126322002 @default.
• W2021517488 hasConcept C142462285 @default.
• W2021517488 hasConcept C203014093 @default.
• W2021517488 hasConcept C2776694085 @default.
• W2021517488 hasConcept C2777478134 @default.
• W2021517488 hasConcept C2777767877 @default.
• W2021517488 hasConcept C2777983669 @default.
• W2021517488 hasConcept C2778690821 @default.
• W2021517488 hasConcept C2779690655 @default.
• W2021517488 hasConcept C2780727368 @default.
• W2021517488 hasConcept C3013748606 @default.
• W2021517488 hasConcept C71924100 @default.
• W2021517488 hasConcept C90924648 @default.
• W2021517488 hasConceptScore W2021517488C126322002 @default.
• W2021517488 hasConceptScore W2021517488C142462285 @default.
• W2021517488 hasConceptScore W2021517488C203014093 @default.
• W2021517488 hasConceptScore W2021517488C2776694085 @default.
• W2021517488 hasConceptScore W2021517488C2777478134 @default.
• W2021517488 hasConceptScore W2021517488C2777767877 @default.
• W2021517488 hasConceptScore W2021517488C2777983669 @default.
• W2021517488 hasConceptScore W2021517488C2778690821 @default.
• W2021517488 hasConceptScore W2021517488C2779690655 @default.

• next